DEDN6526A

DEDN6526A is an antibody-drug conjugate (ADC) consisting of the humanized anti-ETBR antibody DEDN6526A (RG-7636) and the tubulin inhibitor MMAE (McMMAF) (HY-15575). DEDN6526A induces apoptosis and can be used in melanoma research[1].

Product Specifications

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Apoptosis; Endothelin Receptor; Microtubule/Tubulin

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[DEDN6526A]

References & Citations

[1]Sandhu S, et al. Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. Invest New Drugs. 2020 Jun;38 (3) :844-854.

Shipping Conditions

Room temperature

Scientific Category

ADC Related

Clinical Information

Phase 1